Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

500 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.
Shah N, Aiello J, Avigan DE, Berdeja JG, Borrello IM, Chari A, Cohen AD, Ganapathi K, Gray L, Green D, Krishnan A, Lin Y, Manasanch E, Munshi NC, Nooka AK, Rapoport AP, Smith EL, Vij R, Dhodapkar M. Shah N, et al. Among authors: munshi nc. J Immunother Cancer. 2020 Jul;8(2):e000734. doi: 10.1136/jitc-2020-000734. J Immunother Cancer. 2020. PMID: 32661116 Free PMC article. Clinical Trial.
Biology and therapy of multiple myeloma in 1996.
Barlogie B, Jagannath S, Epstein J, Munshi N, Siegel D, Desikan KR, Feinman R, Hsu PL, von Bremen K, Tricot G. Barlogie B, et al. Semin Hematol. 1997 Jan;34(1 Suppl 1):67-72. Semin Hematol. 1997. PMID: 9122748 Review.
Anti-myeloma activity of pamidronate in vivo.
Dhodapkar MV, Singh J, Mehta J, Fassas A, Desikan KR, Perlman M, Munshi NC, Barlogie B. Dhodapkar MV, et al. Among authors: munshi nc. Br J Haematol. 1998 Nov;103(2):530-2. doi: 10.1046/j.1365-2141.1998.00976.x. Br J Haematol. 1998. PMID: 9827929 Free article.
Recent advances in the treatment of multiple myeloma.
Desikan KR, Dhodapkar MV, Munshi NC, Barlogie B. Desikan KR, et al. Among authors: munshi nc. Curr Opin Hematol. 1999 Jul;6(4):216-21. doi: 10.1097/00062752-199907000-00004. Curr Opin Hematol. 1999. PMID: 10400369 Review.
Antitumor activity of thalidomide in refractory multiple myeloma.
Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B. Singhal S, et al. N Engl J Med. 1999 Nov 18;341(21):1565-71. doi: 10.1056/NEJM199911183412102. N Engl J Med. 1999. PMID: 10564685 Free article. Clinical Trial.
Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone.
Desikan KR, Tricot G, Dhodapkar M, Fassas A, Siegel D, Vesole DH, Jagannath S, Singhal S, Mehta J, Spoon D, Anaissie E, Barlogie B, Munshi N. Desikan KR, et al. Bone Marrow Transplant. 2000 Mar;25(5):483-7. doi: 10.1038/sj.bmt.1702167. Bone Marrow Transplant. 2000. PMID: 10713623 Clinical Trial.
The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E, Hideshima T, Lentzsch S, Davies F, Li C, Weisberg E, Schlossman RL, Richardson PG, Griffin JD, Wood J, Munshi NC, Anderson KC. Lin B, et al. Among authors: munshi nc. Cancer Res. 2002 Sep 1;62(17):5019-26. Cancer Res. 2002. PMID: 12208756
500 results